EUROPE, ASIA PACIFIC, LATIN AMERICA, MIDDLE EAST & AFRICA URINARY TRACT INFECTION (UTI) VACCINE MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2026 - 2033)

The Europe, Asia Pacific, Latin America, Middle East & Africa urinary tract infection (UTI) vaccine market is estimated to be valued at USD 62,785.9 Thousands in 2026 and is expected to reach USD 115,476.0 Thousands by 2033, exhibiting a compound annual growth rate (CAGR) of 11.2% from 2026 to 2033. The Europe, Asia Pacific, Latin America, Middle East & Africa urinary tract infection (UTI) vaccine market is expected to grow at a significant rate during the forecast period owing to the increasing burden of recurrent UTIs, growing antimicrobial resistance and the need for alternatives to repeated antibiotic use. The vaccine development is primarily focused on pathogens such as Escherichia coli, with whole-cell, subunit and conjugate approaches gaining interest in the clinical and research pipelines.

The regional market opportunities are dependent on healthcare infrastructure, disease prevalence, regulatory environments and the availability of preventive therapies. Europe and Asia Pacific will continue to be key markets due to mature healthcare systems and increasing clinical development activities whereas Latin America and the Middle East & Africa are emerging markets with growing healthcare access and uptake of novel preventive therapies.

Market Dynamics

The Europe, Asia Pacific, Latin America, Middle East & Africa urinary tract infection (UTI) vaccine market is primarily driven by rising incidence of recurrent UTIs and growing antimicrobial resistance, which is increasing the need for preventive approaches beyond repeated antibiotic treatment. Advances in vaccine research, growing investment in bacterial vaccine candidates, and increasing clinical focus on Escherichia coli and other uropathogens are supporting market development across key regions.

However, a number of constraints are present in the market, such as limited availability of approved UTI vaccines, long clinical development timeframes and uncertain efficacy across a wide range of bacterial strains. Nevertheless, significant opportunities exist in vaccines targeting recurrent and drug-resistant UTIs, particularly among high-risk adult and elderly populations.

Key Features of the Study

• This report provides in-depth analysis of the Europe, Asia Pacific, Latin America, Middle East & Africa urinary tract infection (UTI) vaccine market, and provides market size (USD Thousands) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the Europe, Asia Pacific, Latin America, Middle East & Africa urinary tract infection (UTI) vaccine market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include INMUNOTEK S.L., OM Pharma SA, Sequoia Vaccines, Inc., GlaxoSmithKline Biologicals SA, Strathmann GmbH & Co. KG, Legacy Pharmaceuticals Switzerland GmbH, CureVac SE, Janssen-Cilag International NV, Sanofi, and GlycoVaxyn AG
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The Europe, Asia Pacific, Latin America, Middle East & Africa urinary tract infection (UTI) vaccine market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the Europe, Asia Pacific, Latin America, Middle East & Africa urinary tract infection (UTI) vaccine market

Market Segmentation

• Vaccine Type Insights (Revenue, USD Th, 2021 - 2033)
  • Bacterial whole-cell Vaccines
  • Subunit Vaccines
  • Conjugate Vaccines
  • Live-Attenuated Vaccines
  • Others
• Pathogen Targeted Insights (Revenue, USD Th, 2021 - 2033)
  • Escherichia coli
  • Klebsiella pneumoniae
  • Pseudomonas aeruginosa
  • Other Targeted Pathogens
• Age Group Insights (Revenue, USD Th, 2021 - 2033)
  • Pediatric
  • Adults
  • Elderly
• Route of Administration Insights (Revenue, USD Th, 2021 - 2033)
  • Parenteral
  • Oral
  • Sublingual
  • Intranasal
• Sales Channel Insights (Revenue, USD Th, 2021 - 2033)
  • Hospitals and Clinic Pharmacies
  • Retail pharmacies
  • Others
• Key Players Insights
  • INMUNOTEK S.L.
  • OM Pharma SA
  • Sequoia Vaccines, Inc.
  • GlaxoSmithKline Biologicals SA
  • Strathmann GmbH & Co. KG
  • Legacy Pharmaceuticals Switzerland GmbH
  • CureVac SE
  • Janssen-Cilag International NV
  • Sanofi
  • GlycoVaxyn AG